Abstract: A vehicle includes a propulsion unit configured to move the vehicle and to change a characteristic of the environment of the vehicle. The vehicle also includes a proximity sensor configured to detect the characteristic of the environment of the vehicle. The characteristic of the environment is changed by operation of the propulsion unit. The vehicle further includes obstacle detection circuitry configured to determine a presence of an obstacle in the vicinity of the vehicle based on a comparison between the detected characteristic of the environment and a reference value.

Abstract: The present disclosure provides an aircraft (10) for flying in a forward direction (F). The aircraft (10) comprises an aircraft body (20), and a wing comprising a first wing portion (30A) and a second wing portion (30B). The first wing portion (30A) and the second wing portion (30B) extend away from the aircraft body (20). The first wing portion (30A) and the second wing portion (30B) are configured to generate a first lift value during level flight of the aircraft (10) in the forward direction (F) when the first wing portion (30A) and the second wing portion (30B) are in an equilibrium position. Each of the first wing portion (30A) and the second wing portion (30B) is flexibly mounted relative to the aircraft body (20) such that when a lift force generated by the first wing portion (30A) changes from the first lift value to a second lift value, the first wing portion (30A) is deflected substantially vertically away from an equilibrium position.

Abstract: A method for assessing whether a test substance or treatment is potentially neuroprotective or anti-oxidant, the method comprising the steps of exposing a cell to the test substance or treatment assessing the TSPO level in the cell, wherein a substance or treatment is considered to be potentially anti-oxidant and/or neuroprotective if the TSPO level is decreased. The method may comprise the step of assessing the level of mitophagy in the cell, wherein a substance or treatment is considered to be anti-oxidant or neuroprotective if the level or induction of mitophagy is increased and the TSPO level is decreased.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: A sole for an item of footwear comprising: •a front portion; •a heel portion; and •a energy absorbing member positioned within the front portion, and having a first position in which the energy absorbing member protrudes from the sole, and a second position in which the energy absorbing member is substantially level with a surface of the sole.

Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

Abstract: A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent.

Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.

Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).

Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.

Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

Abstract: Nucleic acid sequences encoding members of a new subfamily of sulfatases and polypeptides encoded thereby are provided. Compositions and methods of modulating sulfatases of this new subfamily to modify growth properties and differentiation of cells, as well as the ability of cells to prevent viral entry and to prevent recruitment of lymphocytes to a site of inflammation are also provided. The compositions and methods are useful in treating cancer and inhibiting metastases, promoting differentiation of stem cells into muscle, neural and renal cells and inhibiting viral infection and inflammation. In addition, functional embryonic techniques for identification and characterization of developmental regulatory genes such as these sulfatases are provided.